Macrophage Membrane-camouflaged PH-sensitive Nanoparticles for Targeted Therapy of Oral Squamous Cell Carcinoma

Overview

Journal J Nanobiotechnology

Publisher Biomed Central

Specialty Biotechnology

Date 2024 Apr 12

PMID 38610015

Authors

Lin Yang

Hongjiao Li

Aihua Luo

Yao Zhang

Hong Chen

Li Zhu

Deqin Yang

Affiliations

Soon will be listed here.

Abstract

Background: Oral cancer is the most common malignant tumor of the head and neck, and 90% of cases are oral squamous cell carcinoma (OSCC). Chemotherapy is an important component of comprehensive treatment for OSCC. However, the clinical treatment effect of chemotherapy drugs, such as doxorubicin (DOX), is limited due to the lack of tumor targeting and rapid clearance by the immune system. Thus, based on the tumor-targeting and immune evasion abilities of macrophages, macrophage membrane-encapsulated poly(methyl vinyl ether alt maleic anhydride)-phenylboronic acid-doxorubicin nanoparticles (MM@PMVEMA-PBA-DOX NPs), briefly as MM@DOX NPs, were designed to target OSCC. The boronate ester bonds between PBA and DOX responded to the low pH value in the tumor microenvironment, selectively releasing the loaded DOX.

Results: The results showed that MM@DOX NPs exhibited uniform particle size and typical core-shell structure. As the pH decreased from 7.4 to 5.5, drug release increased from 14 to 21%. The in vitro targeting ability, immune evasion ability, and cytotoxicity of MM@DOX NPs were verified in HN6 and SCC15 cell lines. Compared to free DOX, flow cytometry and fluorescence images demonstrated higher uptake of MM@DOX NPs by tumor cells and lower uptake by macrophages. Cell toxicity and live/dead staining experiments showed that MM@DOX NPs exhibited stronger in vitro antitumor effects than free DOX. The targeting and therapeutic effects were further confirmed in vivo. Based on in vivo biodistribution of the nanoparticles, the accumulation of MM@DOX NPs at the tumor site was increased. The pharmacokinetic results demonstrated a longer half-life of 9.26 h for MM@DOX NPs compared to 1.94 h for free DOX. Moreover, MM@DOX NPs exhibited stronger tumor suppression effects in HN6 tumor-bearing mice and good biocompatibility.

Conclusions: Therefore, MM@DOX NPs is a safe and efficient therapeutic platform for OSCC.

Citing Articles

Effects of macrophages in OSCC progression.

Dong X, Dong C, Li B Front Immunol. 2025; 15:1517886.

PMID: 39877372 PMC: 11772471. DOI: 10.3389/fimmu.2024.1517886.

Mitophagy in Doxorubicin-Induced Cardiotoxicity: Insights into Molecular Biology and Novel Therapeutic Strategies.

Zhang H, Xie S, Deng W Biomolecules. 2025; 14(12.

PMID: 39766321 PMC: 11674137. DOI: 10.3390/biom14121614.

References

Saiyin W, Wang D, Li L, Zhu L, Liu B, Sheng L . Sequential release of autophagy inhibitor and chemotherapeutic drug with polymeric delivery system for oral squamous cell carcinoma therapy. Mol Pharm. 2014; 11(5):1662-75. DOI: 10.1021/mp5000423. View

Su Z, Liu D, Chen L, Zhang J, Ru L, Chen Z . CD44-Targeted Magnetic Nanoparticles Kill Head And Neck Squamous Cell Carcinoma Stem Cells In An Alternating Magnetic Field. Int J Nanomedicine. 2019; 14:7549-7560. PMC: 6754337. DOI: 10.2147/IJN.S215087. View

Xu Y, Du L, Han B, Wang Y, Fei J, Xia K . Black phosphorus quantum dots camouflaged with platelet-osteosarcoma hybrid membrane and doxorubicin for combined therapy of osteosarcoma. J Nanobiotechnology. 2023; 21(1):243. PMC: 10386629. DOI: 10.1186/s12951-023-02016-9. View

Aznar E, Marcos M, Martinez-Manez R, Sancenon F, Soto J, Amoros P . pH- and photo-switched release of guest molecules from mesoporous silica supports. J Am Chem Soc. 2009; 131(19):6833-43. DOI: 10.1021/ja810011p. View

Ngandeu Neubi G, Opoku-Damoah Y, Gu X, Han Y, Zhou J, Ding Y . Bio-inspired drug delivery systems: an emerging platform for targeted cancer therapy. Biomater Sci. 2018; 6(5):958-973. DOI: 10.1039/C8BM00175H. View

Zhao H, Li L, Zhang J, Zheng C, Ding K, Xiao H . C-C Chemokine Ligand 2 (CCL2) Recruits Macrophage-Membrane-Camouflaged Hollow Bismuth Selenide Nanoparticles To Facilitate Photothermal Sensitivity and Inhibit Lung Metastasis of Breast Cancer. ACS Appl Mater Interfaces. 2018; 10(37):31124-31135. DOI: 10.1021/acsami.8b11645. View

Qian B, Li J, Zhang H, Kitamura T, Zhang J, Campion L . CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011; 475(7355):222-5. PMC: 3208506. DOI: 10.1038/nature10138. View

Chen H, Deng J, Yao X, He Y, Li H, Jian Z . Bone-targeted erythrocyte-cancer hybrid membrane-camouflaged nanoparticles for enhancing photothermal and hypoxia-activated chemotherapy of bone invasion by OSCC. J Nanobiotechnology. 2021; 19(1):342. PMC: 8549398. DOI: 10.1186/s12951-021-01088-9. View

Yoneda T, Hiasa M, Nagata Y, Okui T, White F . Contribution of acidic extracellular microenvironment of cancer-colonized bone to bone pain. Biochim Biophys Acta. 2015; 1848(10 Pt B):2677-84. PMC: 5356024. DOI: 10.1016/j.bbamem.2015.02.004. View

10.

Liang B, Deng T, Li J, Ouyang X, Na W, Deng D . Biomimetic theranostic strategy for anti-metastasis therapy of breast cancer via the macrophage membrane camouflaged superparticles. Mater Sci Eng C Mater Biol Appl. 2020; 115:111097. DOI: 10.1016/j.msec.2020.111097. View

11.

Zhang X, Xu X, Liu H, Ni N, Liu S, Gong Y . CCR2-overexpressing biomimetic carrier-free nanoplatform for enhanced cascade ferroptosis tumor therapy. Acta Biomater. 2023; 166:604-614. DOI: 10.1016/j.actbio.2023.05.006. View

12.

Nakatsumi H, Matsumoto M, Nakayama K . Noncanonical Pathway for Regulation of CCL2 Expression by an mTORC1-FOXK1 Axis Promotes Recruitment of Tumor-Associated Macrophages. Cell Rep. 2017; 21(9):2471-2486. DOI: 10.1016/j.celrep.2017.11.014. View

13.

Chen Q, Zhang X, Massague J . Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell. 2011; 20(4):538-49. PMC: 3293160. DOI: 10.1016/j.ccr.2011.08.025. View

14.

Poudel K, Banstola A, Gautam M, Soe Z, Phung C, Pham L . Macrophage-Membrane-Camouflaged Disintegrable and Excretable Nanoconstruct for Deep Tumor Penetration. ACS Appl Mater Interfaces. 2020; 12(51):56767-56781. DOI: 10.1021/acsami.0c17235. View

15.

Gewirtz D . A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol. 1999; 57(7):727-41. DOI: 10.1016/s0006-2952(98)00307-4. View

16.

Chen X, Zhang X, Liu Q, Zhang J, Zhou G . Nanotechnology: a promising method for oral cancer detection and diagnosis. J Nanobiotechnology. 2018; 16(1):52. PMC: 5994839. DOI: 10.1186/s12951-018-0378-6. View

17.

Wu Y, Wan S, Yang S, Hu H, Zhang C, Lai J . Macrophage cell membrane-based nanoparticles: a new promising biomimetic platform for targeted delivery and treatment. J Nanobiotechnology. 2022; 20(1):542. PMC: 9794113. DOI: 10.1186/s12951-022-01746-6. View

18.

Ma J, Liu Y, Yang X, Zhang C, Zhang Z, Zhong L . Induction chemotherapy in patients with resectable head and neck squamous cell carcinoma: a meta-analysis. World J Surg Oncol. 2013; 11:67. PMC: 3601969. DOI: 10.1186/1477-7819-11-67. View

19.

Cassetta L, Pollard J . Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discov. 2018; 17(12):887-904. DOI: 10.1038/nrd.2018.169. View

20.

Li Y, Liu Y, Xu J, Chen D, Wu T, Cao Y . Macrophage-Cancer Hybrid Membrane-Camouflaged Nanoplatforms for HIF-1α Gene Silencing-Enhanced Sonodynamic Therapy of Glioblastoma. ACS Appl Mater Interfaces. 2023; 15(26):31150-31158. DOI: 10.1021/acsami.3c03001. View